Hercules Capital, Inc. (NASDAQ: HTGC) disclosed that its Chief Financial Officer, Seth H Meyer, purchased 14,000 shares of common stock on February 27, 2026, according to a Form 4/A filed with the Securities and Exchange Commission. The shares were acquired at an average price of $14.33 each, producing a total transaction value of $200,620. Reported trade prices ranged from $14.30 to $14.35. After the purchase, Meyer directly holds 448,553 shares of the business development company.
The insider buy arrives against a backdrop of a weakening stock price - HTGC has lost 22% of its value over the last 12 months and is down nearly 20% year-to-date. Market indicators cited by InvestingPro Tips place the stock's relative strength index in oversold territory. Hercules Capital offers a substantial dividend yield of 12.88% and, according to the same data provider, has paid dividends for 22 consecutive years. InvestingPro also offers an additional 10 tips for investors in HTGC.
On the operational and portfolio front, Hercules Capital released preliminary estimates for its fourth quarter and year-end financials. The firm projects net asset value (NAV) per share between $12.10 and $12.16, representing an increase of $0.05 to $0.11 per share compared with the prior quarter.
Separately, the company amended a loan agreement with Savara Inc., establishing access to up to an additional $75 million of funding. That commitment is contingent upon the U.S. Food and Drug Administration granting approval for Savara's investigational therapy, MOLBREEVI, which the company says would support potential launch activities for the drug.
Investor sentiment appears mixed. Piper Sandler recently downgraded Hercules Capital from Overweight to Neutral and lowered its price target to $17.50 from $20.50. The firm attributed the downgrade to concerns about Hercules Capital's concentrated exposure to the software sector, which Piper Sandler views as vulnerable to disruption risks related to artificial intelligence.
Adding to scrutiny, a short report from Hunterbrook raised questions about the valuation of the company's software-linked debt and the sustainability of its dividend. That report notes that 35% of Hercules' loan portfolio is tied to software-related debt, which the short seller says is marked at full value despite broader industry headwinds.
Collectively, the insider purchase, NAV revision, amended Savara credit facility conditional on FDA approval, analyst downgrade, and the short report frame the current investor narrative around Hercules Capital. The company continues to present a high-yield profile and modest quarter-over-quarter NAV improvement while also facing third-party concerns about sector concentration and asset valuation.